MENA Metabolic Conference
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

shutterstock 2169753685

Yamaha Motor sets up new company to better analyse antibodies in blood

, 27 October 2023/in E-News /by panglobal

Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/shutterstock_2169753685.jpg 793 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-27 09:08:482023-10-27 09:08:48Yamaha Motor sets up new company to better analyse antibodies in blood
Scherm­afbeelding 2023 10 27 om 11.04.19

Merck to pay Daiichi Sankyo up to $22bn to collaborate on 3 new cancer drugs

, 27 October 2023/in E-News /by panglobal

In a deal potentially worth up to US$22 billion, Merck (known as MSD outside of the United States and Canada) has entered into a collaboration agreement with Japan-based Daiichi Sankyo to co-develop and co-commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/Scherm­afbeelding-2023-10-27-om-11.04.19.png 518 1588 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-27 08:59:062023-10-27 09:05:15Merck to pay Daiichi Sankyo up to $22bn to collaborate on 3 new cancer drugs
2302PKL24Oct PharmaKure submits for Alzheimers Disease Combined Drug Clinical Trial

PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients with mild cognitive impairment

, 25 October 2023/in E-News /by panglobal

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/2302PKL24Oct-PharmaKure-submits-for-Alzheimers-Disease-Combined-Drug-Clinical-Trial.jpg 549 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-25 08:35:162024-08-21 13:43:31PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients with mild cognitive impairment
Afbeelding1

Fapon and Halodoc Forge Strategic Partnership to Drive the Development of Indonesia’s In-Vitro Diagnostics Industry

, 19 October 2023/in E-News /by panglobal

Fapon, a leading life-science organization, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform in Indonesia. This partnership brings together Fapon’s expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc’s strong sales channels and local service provisions. The partnership aims to enhance the healthcare standards in Indonesia, benefit local communities, and […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/Afbeelding1.jpg 343 375 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-19 11:13:022024-08-21 13:44:31Fapon and Halodoc Forge Strategic Partnership to Drive the Development of Indonesia’s In-Vitro Diagnostics Industry
shutterstock 531008755

Researchers show association between hypoxia induced by hyperglycaemia and impaired insulin secretion in type 2 diabetes

, 3 October 2023/in E-News /by panglobal

Type 2 diabetes (T2D) is a chronic metabolic disorder that affects more than 500 million people worldwide. It is characterized by insulin resistance, a condition where the cells of the body fail to respond to insulin, resulting in hyperglycaemia.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/shutterstock_531008755.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-03 11:23:262023-10-11 08:32:19Researchers show association between hypoxia induced by hyperglycaemia and impaired insulin secretion in type 2 diabetes
spine cord regeneration

Neuro scientists reverse paralysis by regenerating nerves across complete spinal cord injury

, 3 October 2023/in E-News /by panglobal

Scientists at .NeuroRestore, Switzerland, report in the 22 September 2023 issue of Science [1] that they have developed a gene therapy that was proven in mice to stimulate nerve regrowth across spinal cord injuries and guide nerves to reconnect to their natural targets to restore mobility.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/spine-cord-regeneration.jpg 1088 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-03 11:19:362023-10-03 11:20:40Neuro scientists reverse paralysis by regenerating nerves across complete spinal cord injury
beating heart

How does the heart start beating? Researchers solve the age-old mystery

, 3 October 2023/in E-News /by panglobal

Becoming a full-fledged organism out of a handful of cells, complete with functioning tissues and organs, is a messy yet highly synchronized process that requires cells to organize themselves in a precise manner and begin working together.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/beating_heart.jpg 800 992 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-03 11:14:222023-10-03 11:14:22How does the heart start beating? Researchers solve the age-old mystery
Scherm­afbeelding 2023 10 02 om 16.47.33

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

, 2 October 2023/in E-News /by panglobal

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has updated its flagship platform, Cyto-Mine, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA. By meeting these requirements, the company now provides a solution to increase efficiency and productivity of cell […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/Scherm­afbeelding-2023-10-02-om-16.47.33.jpg 1462 1854 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-02 14:48:462023-10-02 14:48:46Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows
CN Bio Tomasz Kostrzewski

CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for micro-physiological systems

, 2 October 2023/in E-News /by panglobal

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), and LifeNet Health LifeSciences, a non-profit, global leader in human research solutions, will collaborate to supply validated primary human cells for use with CN Bio’s PhysioMimix OOC range of MPS. Under the agreement, LifeNet Health’s high-quality, MPS validated, hepatic […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/CN-Bio-Tomasz-Kostrzewski.jpg 830 553 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-02 14:44:452023-10-02 14:44:45CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for micro-physiological systems
ISSCR check list

ISSCR introduces checklist to promote global best practices for human stem cell research

, 2 October 2023/in E-News /by panglobal

ISSCR introduces checklist to promote global best practices for human stem cell research Recommendations from the Standards for Human Stem Cell Use in Research [1],  published in June by the International Society for Stem Cell Research (ISSCR), include a publishing “checklist” that is now being used by laboratory scientists and implemented in the review process […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/10/ISSCR-check-list.jpg 1128 1522 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-10-02 14:38:512023-10-02 14:38:51ISSCR introduces checklist to promote global best practices for human stem cell research
Page 34 of 231«‹3233343536›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

March 2026

CLi Cover MRCH 2026
11 March 2026

Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction

11 March 2026

Androgen testing for PCOS diagnosis

9 March 2026

DiaSys Diagnostic Systems | ACE FS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription